Skip to main content
Top
Published in:

Open Access 23-04-2024 | Progesterone

Diagnostic and therapeutic use of oral micronized progesterone in endocrinology

Authors: Eleni Memi, Polina Pavli, Maria Papagianni, Nikolaos Vrachnis, George Mastorakos

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2024

Login to get access

Abstract

Progesterone is a natural steroid hormone, while progestins are synthetic molecules. In the female reproductive system, progesterone contributes to the control of luteinizing hormone and follicle-stimulating hormone secretion and their pulsatility, via its receptors on the kisspeptin, neurokinin B, and dynorphin neurons in the hypothalamus. Progesterone together with estradiol controls the cyclic changes of proliferation and decidualization of the endometrium; exerts anti-mitogenic actions on endometrial epithelial cells; regulates normal menstrual bleeding; contributes to fertilization and pregnancy maintenance; participates in the onset of labor. In addition, it exerts numerous effects on other endocrine systems. Micronized progesterone (MP) is natural progesterone with increased bioavailability, due to its pharmacotechnical micronized structure, which makes it an attractive diagnostic and therapeutic tool. This critical literature review aims to summarize and put forward the potential diagnostic and therapeutic uses of MP in the field of endocrinology. During reproductive life, MP is used for diagnostic purposes in the evaluation of primary or secondary amenorrhea as a challenge test. Moreover, it can be prescribed to women presenting with amenorrhea or oligomenorrhea for induction of withdrawal bleeding, in order to time blood-sampling for diagnostic purposes in early follicular phase. Therapeutically, MP, alone or combined with estrogens, is a useful tool in various endocrine disorders including primary amenorrhea, abnormal uterine bleeding due to disordered ovulation, luteal phase deficiency, premenstrual syndrome, polycystic ovary syndrome, secondary amenorrhea [functional hypothalamic amenorrhea, premature ovarian insufficiency], perimenopause and menopause. When administrated per os, acting as a neurosteroid directly or through its metabolites, it exerts beneficial effects on brain function such as alleviation of symptoms of anxiety and depression, asw well as of sleep problems, while it improves working memory in peri- and menopausal women. Micronized progesterone preserves full potential of progesterone activity, without presenting many of the side-effects of progestins. Although it has been associated with more frequent drowsiness and dizziness, it can be well tolerated with nocturnal administration. Because of its better safety profile, especially with regard to metabolic ailments, breast cancer risk and veno-thromboembolism risk, MP is the preferred option for individuals with an increased risk of cardiovascular and metabolic diseases and of all-cause mortality.
Literature
1.
go back to reference McAuley JW, Kroboth FJ, Kroboth PD. Oral administration of micronized progesterone:a review and more experience. Pharmacotherapy. 1996;16:453–7.PubMedCrossRef McAuley JW, Kroboth FJ, Kroboth PD. Oral administration of micronized progesterone:a review and more experience. Pharmacotherapy. 1996;16:453–7.PubMedCrossRef
13.
go back to reference Kuhl H. Pharmacology of progestins. Basic aspects-progesterone derivatives. Menopause Rev. 2001;6:9–16. Kuhl H. Pharmacology of progestins. Basic aspects-progesterone derivatives. Menopause Rev. 2001;6:9–16.
14.
go back to reference Kudwa AE, Rissman EF. Double oestrogen receptor alpha and beta knockout mice reveal differences in neural oestrogen-mediated progestin receptor induction and female sexual behaviour. J Neuroendocrinol. 2003;15:978–83.PubMedCrossRef Kudwa AE, Rissman EF. Double oestrogen receptor alpha and beta knockout mice reveal differences in neural oestrogen-mediated progestin receptor induction and female sexual behaviour. J Neuroendocrinol. 2003;15:978–83.PubMedCrossRef
16.
go back to reference Acharya KD, Finkelstein SD, Bless EP, Nettles SA, Mulac-Jericevic B, Conneely OM, Mani SK, Tetel MJ. Estradiol preferentially induces progestin Receptor-A (PR-A) over PR-B in cells expressing nuclear receptor coactivators in the female mouse hypothalamus. eNeuro. 2015. https://doi.org/10.1523/ENEURO.0012-15.2015. Acharya KD, Finkelstein SD, Bless EP, Nettles SA, Mulac-Jericevic B, Conneely OM, Mani SK, Tetel MJ. Estradiol preferentially induces progestin Receptor-A (PR-A) over PR-B in cells expressing nuclear receptor coactivators in the female mouse hypothalamus. eNeuro. 2015. https://​doi.​org/​10.​1523/​ENEURO.​0012-15.​2015.
27.
go back to reference Prior JC, Seifert-Klauss VR, Giustini D, Adachi JD, Kalyan S, Goshtasebi A. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy - a systematic review and meta-analysis of controlled trials with direct randomization. J Musculoskelet Neuronal Interact. 2017;17:146–54.PubMedPubMedCentral Prior JC, Seifert-Klauss VR, Giustini D, Adachi JD, Kalyan S, Goshtasebi A. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy - a systematic review and meta-analysis of controlled trials with direct randomization. J Musculoskelet Neuronal Interact. 2017;17:146–54.PubMedPubMedCentral
28.
go back to reference Poulin R, Baker D, Poirier D, Labrie F. Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat. 1989;13:161–72.PubMedCrossRef Poulin R, Baker D, Poirier D, Labrie F. Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat. 1989;13:161–72.PubMedCrossRef
35.
go back to reference Pan DS, Liu WG, Yang XF, Cao F. Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury. Biomed Environ Sci. 2007;20:432–8.PubMed Pan DS, Liu WG, Yang XF, Cao F. Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury. Biomed Environ Sci. 2007;20:432–8.PubMed
37.
go back to reference Malik S, Krishnaprasad K. Natural micronized progesterone sustained release (SR) and Luteal Phase: Role Redefined!! J Clin Diagn Res. 2016;10:QE01–4.PubMedPubMedCentral Malik S, Krishnaprasad K. Natural micronized progesterone sustained release (SR) and Luteal Phase: Role Redefined!! J Clin Diagn Res. 2016;10:QE01–4.PubMedPubMedCentral
38.
go back to reference Simon JA, Robinson DE, Andrews MC, Hildebrand JR 3rd, Rocci ML Jr, Blake RE, Hodgen GD. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril. 1993;60:26–33.PubMedCrossRef Simon JA, Robinson DE, Andrews MC, Hildebrand JR 3rd, Rocci ML Jr, Blake RE, Hodgen GD. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril. 1993;60:26–33.PubMedCrossRef
40.
go back to reference Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. Acta Obstet Gynecol Scand Suppl. 1984;127:1–37.PubMedCrossRef Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. Acta Obstet Gynecol Scand Suppl. 1984;127:1–37.PubMedCrossRef
41.
go back to reference Padwick ML, Endacott J, Matson C, Whitehead MI. Absorption and metabolism of oral progesterone when administered twice daily. Fertil Steril. 1986;46:402–7.PubMedCrossRef Padwick ML, Endacott J, Matson C, Whitehead MI. Absorption and metabolism of oral progesterone when administered twice daily. Fertil Steril. 1986;46:402–7.PubMedCrossRef
42.
go back to reference Morville R, Dray F, Reynier J, Barrat J. Biodisponibilité De La progestérone naturelle administrée par voie orale. Mesure des concentrations du stéroïde dans le plasma, l’endomètre et le tissu mammaire [The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue]. J Gynecol Obstet Biol Reprod (Paris). 1982;1:355–63. Morville R, Dray F, Reynier J, Barrat J. Biodisponibilité De La progestérone naturelle administrée par voie orale. Mesure des concentrations du stéroïde dans le plasma, l’endomètre et le tissu mammaire [The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue]. J Gynecol Obstet Biol Reprod (Paris). 1982;1:355–63.
48.
go back to reference Shangold MM, Tomai TP, Cook JD, Jacobs SL, Zinaman MJ, Chin SY, Simon JA. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril. 1991;56:1040–7.PubMedCrossRef Shangold MM, Tomai TP, Cook JD, Jacobs SL, Zinaman MJ, Chin SY, Simon JA. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril. 1991;56:1040–7.PubMedCrossRef
50.
go back to reference Master-Hunter T, Heiman DL. Amenorrhea: evaluation and treatment. Am Fam Physician. 2006;73:1374–82.PubMed Master-Hunter T, Heiman DL. Amenorrhea: evaluation and treatment. Am Fam Physician. 2006;73:1374–82.PubMed
52.
go back to reference Fritz MA, Speroff L. Amenorrhea. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2011. Fritz MA, Speroff L. Amenorrhea. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2011.
55.
go back to reference Practice Committee of American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril. 2008;90:219–25.CrossRef Practice Committee of American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril. 2008;90:219–25.CrossRef
56.
go back to reference Nezi M, Christopoulos P, Paltoglou G, Gryparis A, Bakoulas V, Deligeoroglou E, Creatsas G, Mastorakos G. Focus on BMI and subclinical hypothyroidism in adolescent girls first examined for amenorrhea or oligomenorrhea. The emerging role of polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2016. https://doi.org/10.1515/jpem-2015-0312.CrossRefPubMed Nezi M, Christopoulos P, Paltoglou G, Gryparis A, Bakoulas V, Deligeoroglou E, Creatsas G, Mastorakos G. Focus on BMI and subclinical hypothyroidism in adolescent girls first examined for amenorrhea or oligomenorrhea. The emerging role of polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2016. https://​doi.​org/​10.​1515/​jpem-2015-0312.CrossRefPubMed
57.
go back to reference Marsh CA, Grimstad FW. Primary amenorrhea: diagnosis and management. Obstet Gynecol Surv. 2014;69:603–12.PubMedCrossRef Marsh CA, Grimstad FW. Primary amenorrhea: diagnosis and management. Obstet Gynecol Surv. 2014;69:603–12.PubMedCrossRef
60.
go back to reference Federici S, Goggi G, Quinton R, Giovanelli L, Persani L, Cangiano B, Bonomi M. New and Consolidated Therapeutic Options for Pubertal Induction in Hypogonadism: In-depth review of the literature. Endocr Rev. 2022;43:824–51.PubMedCrossRef Federici S, Goggi G, Quinton R, Giovanelli L, Persani L, Cangiano B, Bonomi M. New and Consolidated Therapeutic Options for Pubertal Induction in Hypogonadism: In-depth review of the literature. Endocr Rev. 2022;43:824–51.PubMedCrossRef
64.
go back to reference Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC. Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med. 1994;96:521–30.PubMedCrossRef Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC. Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med. 1994;96:521–30.PubMedCrossRef
65.
go back to reference Prior JC. Adaptive, reversible, hypothalamic reproductive suppression: more than functional hypothalamic amenorrhea. Front Endocrinol (Lausanne). 2022;13:893889.PubMedCrossRef Prior JC. Adaptive, reversible, hypothalamic reproductive suppression: more than functional hypothalamic amenorrhea. Front Endocrinol (Lausanne). 2022;13:893889.PubMedCrossRef
66.
go back to reference Munro MG, Critchley HOD, Fraser IS, FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018. https://doi.org/10.1002/ijgo.12666.CrossRefPubMed Munro MG, Critchley HOD, Fraser IS, FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018. https://​doi.​org/​10.​1002/​ijgo.​12666.CrossRefPubMed
68.
go back to reference ACOG Committee on Adolescent Health Care. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol. 2006;108:1323–8. ACOG Committee Opinion 349, November 2006. ACOG Committee on Adolescent Health Care. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol. 2006;108:1323–8. ACOG Committee Opinion 349, November 2006.
70.
go back to reference Management of abnormal uterine bleeding associated with ovulatory dysfunction. Practice Bulletin 136. American College of Obstetricians and gynecologists. Obstet Gynecol. 2013;122:176–85. Management of abnormal uterine bleeding associated with ovulatory dysfunction. Practice Bulletin 136. American College of Obstetricians and gynecologists. Obstet Gynecol. 2013;122:176–85.
79.
go back to reference Biggs WS, Demuth RH. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2011;84:918–24.PubMed Biggs WS, Demuth RH. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2011;84:918–24.PubMed
82.
go back to reference Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209–16.PubMedCrossRef Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209–16.PubMedCrossRef
84.
go back to reference Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986;232:1004–7.PubMedCrossRef Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986;232:1004–7.PubMedCrossRef
88.
go back to reference de Lignieres B, Dennerstein L, Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas. 1995;21:251–7.PubMedCrossRef de Lignieres B, Dennerstein L, Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas. 1995;21:251–7.PubMedCrossRef
91.
go back to reference Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274:51–7.PubMedCrossRef Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274:51–7.PubMedCrossRef
94.
go back to reference Geber H. Einege Daten Zur Pathologie Der Urticaria menstrationalis. Dermat Z. 1921;32:143.CrossRef Geber H. Einege Daten Zur Pathologie Der Urticaria menstrationalis. Dermat Z. 1921;32:143.CrossRef
103.
go back to reference Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. 2000;85:4047–52.PubMed Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. 2000;85:4047–52.PubMed
104.
105.
go back to reference Bagis T, Gokcel A, Zeyneloglu HB, Tarim E, Kilicdag EB, Haydardedeoglu B. The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study. J Clin Endocrinol Metab. 2002. https://doi.org/10.1210/jc.2002-020294.CrossRefPubMed Bagis T, Gokcel A, Zeyneloglu HB, Tarim E, Kilicdag EB, Haydardedeoglu B. The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study. J Clin Endocrinol Metab. 2002. https://​doi.​org/​10.​1210/​jc.​2002-020294.CrossRefPubMed
106.
110.
go back to reference Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf). 2000;52:587–94.PubMedCrossRef Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf). 2000;52:587–94.PubMedCrossRef
114.
go back to reference Caronia LM, Martin C, Welt CK, Sykiotis GP, Quinton R, Thambundit A, Avbelj M, Dhruvakumar S, Plummer L, HughesVA, Seminara SB, Boepple PA, Sidis Y, Crowley WF Jr, Martin KA, Hall JE, Pitteloud N. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med. 2011;364:215–25.PubMedPubMedCentralCrossRef Caronia LM, Martin C, Welt CK, Sykiotis GP, Quinton R, Thambundit A, Avbelj M, Dhruvakumar S, Plummer L, HughesVA, Seminara SB, Boepple PA, Sidis Y, Crowley WF Jr, Martin KA, Hall JE, Pitteloud N. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med. 2011;364:215–25.PubMedPubMedCentralCrossRef
116.
go back to reference Cobb KL, Bachrach LK, Sowers M, Nieves J, Greendale GA, Kent KK, Brown BWJr, Pettit K, Harper DM, Kelsey JL. The effect of oral contraceptives on bone mass and stress fractures in female runners. Med Sci Sports Exerc. 2007;39:1464–73.PubMedCrossRef Cobb KL, Bachrach LK, Sowers M, Nieves J, Greendale GA, Kent KK, Brown BWJr, Pettit K, Harper DM, Kelsey JL. The effect of oral contraceptives on bone mass and stress fractures in female runners. Med Sci Sports Exerc. 2007;39:1464–73.PubMedCrossRef
117.
go back to reference Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, Klibanski A. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Min Res. 2011;26:2430–8.CrossRef Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, Klibanski A. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Min Res. 2011;26:2430–8.CrossRef
119.
go back to reference Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67:604–6.PubMed Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67:604–6.PubMed
120.
go back to reference Bompoula MS, Valsamakis G, Neofytou S, Messaropoulos P, Salakos N, Mastorakos G, Kalantaridou SN. Demographic, clinical and hormonal characteristics of patients with premature ovarian insufficiency and those of early menopause: data from two tertiary premature ovarian insufficiency centers in Greece. Gynecol Endocrinol. 2020. https://doi.org/10.1080/09513590.2020.1739266.CrossRefPubMed Bompoula MS, Valsamakis G, Neofytou S, Messaropoulos P, Salakos N, Mastorakos G, Kalantaridou SN. Demographic, clinical and hormonal characteristics of patients with premature ovarian insufficiency and those of early menopause: data from two tertiary premature ovarian insufficiency centers in Greece. Gynecol Endocrinol. 2020. https://​doi.​org/​10.​1080/​09513590.​2020.​1739266.CrossRefPubMed
121.
go back to reference Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014;124:193–7. Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014;124:193–7.
122.
go back to reference Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. ESHRE Guideline: management of women with premature ovarian insufficiency. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. Hum Reprod. 2016. https://doi.org/10.1093/humrep/dew027.CrossRefPubMed Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. ESHRE Guideline: management of women with premature ovarian insufficiency. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. Hum Reprod. 2016. https://​doi.​org/​10.​1093/​humrep/​dew027.CrossRefPubMed
123.
go back to reference Committee Opinion No. 698: hormone therapy in primary ovarian insufficiency. Obstet Gynecol. 2017;129:134–41.CrossRef Committee Opinion No. 698: hormone therapy in primary ovarian insufficiency. Obstet Gynecol. 2017;129:134–41.CrossRef
124.
go back to reference Mittal M, Savvas M, Arya R, McEniery C, Narvekar N, Cardozo L, Panay N, Hamoda H. A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: study protocol and review of the literature. Menopause Int. 2013. https://doi.org/10.1177/1754045313503635.CrossRefPubMed Mittal M, Savvas M, Arya R, McEniery C, Narvekar N, Cardozo L, Panay N, Hamoda H. A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: study protocol and review of the literature. Menopause Int. 2013. https://​doi.​org/​10.​1177/​1754045313503635​.CrossRefPubMed
125.
go back to reference Mittal M, Chitongo P, Supramaniam PR, Cardozo L, Savvas M, Panay N, Arya R, Hamoda H. The effect of micronized progesterone and medroxyprogesterone acetate in combination with transdermal estradiol on hemostatic biomarkers in postmenopausal women diagnosed with POI and early menopause: a randomized trial. Menopause. 2022;29:580–9.PubMedCrossRef Mittal M, Chitongo P, Supramaniam PR, Cardozo L, Savvas M, Panay N, Arya R, Hamoda H. The effect of micronized progesterone and medroxyprogesterone acetate in combination with transdermal estradiol on hemostatic biomarkers in postmenopausal women diagnosed with POI and early menopause: a randomized trial. Menopause. 2022;29:580–9.PubMedCrossRef
126.
127.
go back to reference Mittal M, Panay N, Supramaniam PR, Savvas M, Cardozo L, Hamoda H. A direct comparison of women’s perceptions and acceptability of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol in the management of young postmenopausal women, under 45 years of age. Post Reprod Health. 2020. https://doi.org/10.1177/2053369120960960.CrossRefPubMed Mittal M, Panay N, Supramaniam PR, Savvas M, Cardozo L, Hamoda H. A direct comparison of women’s perceptions and acceptability of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol in the management of young postmenopausal women, under 45 years of age. Post Reprod Health. 2020. https://​doi.​org/​10.​1177/​2053369120960960​.CrossRefPubMed
129.
go back to reference Fatemi HM, Bourgain C, Donoso P, Blockeel C, Papanikolaou EG, Popovic-Todorovic B, Devroey P. Effect of oral administration of dydrogestrone versus vaginal administration of natural micronized progesterone on the secretory transformation of endometrium and luteal endocrine profile in patients with premature ovarian failure: a proof of concept. Hum Reprod. 2007. https://doi.org/10.1093/humrep/del520.CrossRefPubMed Fatemi HM, Bourgain C, Donoso P, Blockeel C, Papanikolaou EG, Popovic-Todorovic B, Devroey P. Effect of oral administration of dydrogestrone versus vaginal administration of natural micronized progesterone on the secretory transformation of endometrium and luteal endocrine profile in patients with premature ovarian failure: a proof of concept. Hum Reprod. 2007. https://​doi.​org/​10.​1093/​humrep/​del520.CrossRefPubMed
135.
go back to reference Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2008;61:171–80.PubMedCrossRef Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2008;61:171–80.PubMedCrossRef
138.
go back to reference Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev. 1998;19:397–428.PubMedCrossRef Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev. 1998;19:397–428.PubMedCrossRef
139.
go back to reference Prior JC. The ageing female reproductive axis II: ovulatory changes with perimenopause. Novartis Found Symp. 2002;242:172–86. Prior JC. The ageing female reproductive axis II: ovulatory changes with perimenopause. Novartis Found Symp. 2002;242:172–86.
141.
go back to reference Casper RF, Dodin S, Reid RL. The Effect of 20 µg Ethinyl Estradiol/1 mg norethindrone acetate (MinestrinTM), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic Perimenopausal women. Menopause. 1997;4:139–47. Casper RF, Dodin S, Reid RL. The Effect of 20 µg Ethinyl Estradiol/1 mg norethindrone acetate (MinestrinTM), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic Perimenopausal women. Menopause. 1997;4:139–47.
142.
go back to reference Santoro N, Teal S, Gavito C, Cano S, Chosich J, Sheeder J. Use of a levonorgestrel-containing intrauterine system with supplemental estrogen improves symptoms in perimenopausal women: a pilot study. Menopause. 2015;22:1301–7.PubMedCrossRef Santoro N, Teal S, Gavito C, Cano S, Chosich J, Sheeder J. Use of a levonorgestrel-containing intrauterine system with supplemental estrogen improves symptoms in perimenopausal women: a pilot study. Menopause. 2015;22:1301–7.PubMedCrossRef
143.
go back to reference Prior JC. Progesterone for symptomatic perimenopause treatment - progesterone politics, physiology and potential for perimenopause. Facts Views Vis Obgyn. 2011;3:109–20.PubMedPubMedCentral Prior JC. Progesterone for symptomatic perimenopause treatment - progesterone politics, physiology and potential for perimenopause. Facts Views Vis Obgyn. 2011;3:109–20.PubMedPubMedCentral
145.
go back to reference Kostova P, Zlatkov V. Clinical study on the effect of vaginal administration of MP at dysfunctional uterine bleeding in premenopause. Akush Ginekol. 2009;48:3–7. Kostova P, Zlatkov V. Clinical study on the effect of vaginal administration of MP at dysfunctional uterine bleeding in premenopause. Akush Ginekol. 2009;48:3–7.
149.
go back to reference Magos AL, Brewster E, Singh R, O’Dowd T, Brincat M, Studd JW. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol. 1986;93:1290–6.PubMedCrossRef Magos AL, Brewster E, Singh R, O’Dowd T, Brincat M, Studd JW. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol. 1986;93:1290–6.PubMedCrossRef
150.
go back to reference Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of depressive symptoms in the menopause transition: a Randomized Clinical Trial. JAMA Psychiatry. 2018;75:149–57.PubMedPubMedCentralCrossRef Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of depressive symptoms in the menopause transition: a Randomized Clinical Trial. JAMA Psychiatry. 2018;75:149–57.PubMedPubMedCentralCrossRef
153.
go back to reference Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S, Manson JE, Barnabei VM, Lane DS, Brzyski RG, Rosal MC, Wylie-Rosett J, Hays J. Symptom experience after discontinuing use of estrogen plus progestin. JAMA. 2005;294:183–93.PubMedCrossRef Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S, Manson JE, Barnabei VM, Lane DS, Brzyski RG, Rosal MC, Wylie-Rosett J, Hays J. Symptom experience after discontinuing use of estrogen plus progestin. JAMA. 2005;294:183–93.PubMedCrossRef
154.
160.
go back to reference Prior JC, Elliott TG, Norman E, Stajic V, Hitchcock CL. Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLoS ONE. 2014;9:e84698.PubMedPubMedCentralCrossRef Prior JC, Elliott TG, Norman E, Stajic V, Hitchcock CL. Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLoS ONE. 2014;9:e84698.PubMedPubMedCentralCrossRef
162.
go back to reference Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, Miller VM, Neal-Perry G, Santoro N, Taylor HS, Vittinghoff E, Yan M, Hodis HN. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014. https://doi.org/10.7326/M14-0353.CrossRefPubMed Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, Miller VM, Neal-Perry G, Santoro N, Taylor HS, Vittinghoff E, Yan M, Hodis HN. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014. https://​doi.​org/​10.​7326/​M14-0353.CrossRefPubMed
166.
go back to reference Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms–a placebo-controlled randomized trial in healthy postmenopausal women. Menopause. 2012;19:886–93.PubMedCrossRef Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms–a placebo-controlled randomized trial in healthy postmenopausal women. Menopause. 2012;19:886–93.PubMedCrossRef
168.
go back to reference Di Carlo C, Sammartino A, Di Spiezio Sardo A, Tommaselli GA, Guida M, Mandato VD, D’Elia A, Nappi C. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause. 2005;12:520–5.PubMedCrossRef Di Carlo C, Sammartino A, Di Spiezio Sardo A, Tommaselli GA, Guida M, Mandato VD, D’Elia A, Nappi C. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause. 2005;12:520–5.PubMedCrossRef
171.
go back to reference Sturdee DW, Pines A, Archer DF, Baber RJ, Barlow D, Birkhäuser MH, Brincat M, Cardozo L, de Villiers TJ, Gambacciani M, Gompel AA, Henderson VW, Kluft C, Lobo RA, MacLennan AH, Marsden J, Nappi RE, Panay N, Pickar JH, Robinson D, Simon J, Sitruk-Ware RL, Stevenson JC. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011. https://doi.org/10.3109/13697137.2011.570590.CrossRefPubMed Sturdee DW, Pines A, Archer DF, Baber RJ, Barlow D, Birkhäuser MH, Brincat M, Cardozo L, de Villiers TJ, Gambacciani M, Gompel AA, Henderson VW, Kluft C, Lobo RA, MacLennan AH, Marsden J, Nappi RE, Panay N, Pickar JH, Robinson D, Simon J, Sitruk-Ware RL, Stevenson JC. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011. https://​doi.​org/​10.​3109/​13697137.​2011.​570590.CrossRefPubMed
174.
go back to reference Pan Z, Wen S, Qiao X, Yang M, Shen X, Xu L. Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis. Menopause. 2022;29:627–35.PubMedPubMedCentralCrossRef Pan Z, Wen S, Qiao X, Yang M, Shen X, Xu L. Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis. Menopause. 2022;29:627–35.PubMedPubMedCentralCrossRef
Metadata
Title
Diagnostic and therapeutic use of oral micronized progesterone in endocrinology
Authors
Eleni Memi
Polina Pavli
Maria Papagianni
Nikolaos Vrachnis
George Mastorakos
Publication date
23-04-2024

Other articles of this Issue 4/2024

Reviews in Endocrine and Metabolic Disorders 4/2024 Go to the issue

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Live: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more